Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Impact · against what's priced in

RYTM is approaching a critical binary catalyst with the March 20 PDUFA date. While the supplemental efficacy data is positive, the primary driver for the stock is the imminent FDA decision and subsequent expansion into European and Japanese markets.

RYTM+0.60

No priced-in read yet